%0 Journal Article
%T Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia.
%A Peng Y
%A Huang J
%A Yin J
%A Meng F
%A Cao Y
%A Huang L
%A Li D
%A Zhang Y
%A Zhang D
%A Meng L
%A Han Z
%A Hong Z
%J Expert Rev Hematol
%V 17
%N 4
%D 2024 Apr-May 24
%M 38616308
%F 2.819
%R 10.1080/17474086.2024.2343885
%X <B>UNASSIGNED: </B>Studies on dasatinib-based low-intensity induction regimens and post-remission strategies are limited in China. Therefore, we conducted a single-center phase 2 trial in newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) to establish the efficacy and safety of this treatment approach.<BR><B>UNASSIGNED: </B>Patients received one month of dasatinib plus low-intensity chemotherapy and two months of dasatinib monotherapy for induction, followed by a single course of high-dose methotrexate for consolidation. Subsequently, they underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) or tyrosine kinase inhibitor (TKI)-based treatment for maintenance therapy between October 2015 and August 2022.<BR><B>UNASSIGNED: </B>Twenty-two patients were enrolled. Median age was 45 years (range, 20-71). The rates of major and complete molecular responses in the third month were 18.2% and 40.9% respectively. With a median follow-up of 15 months (range, 5-89), the estimated 3-year disease-free survival (DFS) and overall survival (OS) were 52.4% and 73.2%, respectively. The TKI-based cohort had a significantly poorer DFS (p = 0.014) and OS (p = 0.008) than the allo-HSCT cohort.<BR><B>UNASSIGNED: </B>Our results suggest that dasatinib-based low-intensity chemotherapy is safe and effective as an induction strategy in the Chinese population. Allo-HSCT plays a crucial role in the long-term outcomes of patients with Ph+ ALL.<BR><B>UNASSIGNED: </B>The trial was registered at ClinicalTrials.gov as NCT02690922.